-
1
-
-
0031008896
-
ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)
-
Morris SW, Naeve C, Mathew P, James PL, Kirstein MN, Cui X, et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997;14:2175-88.
-
(1997)
Oncogene
, vol.14
, pp. 2175-2188
-
-
Morris, S.W.1
Naeve, C.2
Mathew, P.3
James, P.L.4
Kirstein, M.N.5
Cui, X.6
-
2
-
-
0028198206
-
Fusion of a kinase gene, ALK, to a nucleolar protein gene. NPM. In non-Hodgkin's lymphoma
-
Morris SW, Kirstein Mol. Fusion of a kinase gene, ALK, to a nucleolar protein gene. NPM. in non-Hodgkin's lymphoma. Science 1994;263:1281-4.
-
(1994)
Science
, vol.263
, pp. 1281-1284
-
-
Morris, S.W.1
Mol, K.2
-
3
-
-
2342635959
-
Anaplastic lymphoma kinase proteins in growth control and cancer
-
Pulford K, Morris SW, Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol 2004;199:330-58.
-
(2004)
J Cell Physiol
, vol.199
, pp. 330-358
-
-
Pulford, K.1
Morris, S.W.2
Turturro, F.3
-
4
-
-
0035419348
-
Role of signal transducer and activator of transcription 5 in nucleophosmin/anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells
-
Nieborowska-Skorska M, Slupianek A, Xue L, Zhang Q, Raghunath PN, Hoser G, et al. Role of signal transducer and activator of transcription 5 in nucleophosmin/anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells. Cancer Res 2001;61:6517-23.
-
(2001)
Cancer Res
, vol.61
, pp. 6517-6523
-
-
Nieborowska-Skorska, M.1
Slupianek, A.2
Xue, L.3
Zhang, Q.4
Raghunath, P.N.5
Hoser, G.6
-
5
-
-
0031755958
-
Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity
-
Bai RY, Dieter P, Peschel C, Morris SW, Duyster J. Nucleophosmin- anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol 1998;18:6951-61.
-
(1998)
Mol Cell Biol
, vol.18
, pp. 6951-6961
-
-
Bai, R.Y.1
Dieter, P.2
Peschel, C.3
Morris, S.W.4
Duyster, J.5
-
6
-
-
0034672140
-
Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway
-
Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 2000;96:4319-27.
-
(2000)
Blood
, vol.96
, pp. 4319-4327
-
-
Bai, R.Y.1
Ouyang, T.2
Miething, C.3
Morris, S.W.4
Peschel, C.5
Duyster, J.6
-
7
-
-
0035990893
-
Protein kinases as targets for anticancer agents: From inhibitors to useful drugs
-
Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, et al. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther 2002;93:79-98.
-
(2002)
Pharmacol Ther
, vol.93
, pp. 79-98
-
-
Fabbro, D.1
Ruetz, S.2
Buchdunger, E.3
Cowan-Jacob, S.W.4
Fendrich, G.5
Liebetanz, J.6
-
8
-
-
0033973544
-
Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro
-
Svingen PA, Tefferi A, Kottke TJ, Kaur G, Narayanan VL, Sausville EA, et al. Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin Cancer Res 2000;6:237-49.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 237-249
-
-
Svingen, P.A.1
Tefferi, A.2
Kottke, T.J.3
Kaur, G.4
Narayanan, V.L.5
Sausville, E.A.6
-
9
-
-
0035871444
-
Phase I trial of 72-hour continuous infusion of UCN-01 in patients with refractory neoplasms
-
Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, et al. Phase I trial of 72-hour continuous infusion of UCN-01 in patients with refractory neoplasms. J Clin Oncol 2001;19:2319-33.
-
(2001)
J Clin Oncol
, vol.19
, pp. 2319-2333
-
-
Sausville, E.A.1
Arbuck, S.G.2
Messmann, R.3
Headlee, D.4
Bauer, K.S.5
Lush, R.M.6
|